While Black and Hispanic families are enthusiastic about research participation, other provider- and systems-focused factors may influence their involvement in pediatric oncology clinical trials, according to a study led by researchers at UT Southwestern Medical Center and Dana-Farber/Mass General.
The SANRECO phase II trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera, met its primary endpoint and secondary endpoints. The 36-week, randomized, double-blind, placebo-controlled portion of the trial administered divesiran subcutaneously (6 mg/kg) every six weeks or every twelve weeks.
